Plasma Lipoprotein-associated Phospholipase A 2 Is Inversely Correlated with Proprotein Convertase Subtilisin-kexin Type 9

Archives of Medical Research

Volumn 43, Issue 1, 2012, Pages 11-14

  Constantinides, Alexander ^a   Kappelle, Paul J W H ^a   Lambert, Gilles ^b,c   Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b HEART RESEARCH INSTITUTE   (Australia)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

Low density lipoprotein cholesterol; Lp PLA 2; PCSK9

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; LIPID METABOLISM; MALE; TURBIDIMETRY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HEALTH; HUMANS; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84859229819     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.01.001     Document Type: Article

References (16)

1. Tellis C.C., Tselepis A.D. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009, 1791:327-338.
2. Thompson A., Gao P., et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010, 375:1536-1544. Lp-PLA(2) Studies Collaboration.
3. Constantinides A., van Pelt L.J., van Leeuwen J.J., et al. Carotid intima media thickness is associated with plasma lipoprotein-associated phospholipase A(2) mass in nondiabetic subjects but not in patients with type 2 diabetes. Eur J Clin Invest 2011, 41:820-827.
4. Tsimihodimos V., Karabina S.A., Tambaki A.P., et al. Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res 2002, 43:258-263.
5. 2: a new target for statin therapy. Curr Atheroscler Rep 2010, 12:29-33.
6. Lambert G., Charlton F., Rye K.A., et al. Molecular basis of PCSK9 function. Atherosclerosis 2009, 203:1-7.
7. Soutar A.K. Unexpected roles for PCSK9 in lipid metabolism. Curr Opin Lipidol 2011, 22:192-196.
8. Chan D.C., Lambert G., Barrett P.H., et al. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?. Clin Chem 2009, 55:2049-2052.
9. Vergès B., Duvillard L., Brindisi M.C., et al. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes. Atherosclerosis 2011, 219:342-348.
10. Lakoski S.G., Lagace T.A., Cohen J.C., et al. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009, 94:2537-2543.
11. Mohler E.R., Ballantyne C.M., Davidson M.H., et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2008, 51:1632-1641.
12. Abifadel M., Pakradouni J., Collin M., et al. Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents. Expert Opin Ther Pat 2010, 20:1547-1571.
13. Horton J.D., Cohen J.C., Hobbs H.H. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009, 50(suppl):S172-S177.
14. Baass A., Dubuc G., Tremblay M., et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009, 55:1637-1645.
15. Brouwers M.C., Troutt J.S., van Greevenbroek M.M., et al. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study. Atherosclerosis 2011, 217:263-267.
16. Markakis K.P., Koropouli M.K., Grammenou-Savvoglou S., et al. Implication of lipoprotein associated phospholipase A2 activity in oxLDL uptake by macrophages. J Lipid Res 2010, 51:2191-2201.